Abbott Laboratories logo
Abbott Laboratories (ABT)
Compare

Abbott Laboratories (ABT) Share Buybacks

The buybacks for Abbott Laboratories (ABT) is $893.00 Million with a year-over-year change of -31.04%. Share buybacks (stock repurchases) represent cash spent by the company to buy back its own shares in the open market, reducing shares outstanding and returning capital to shareholders.

ABT Buybacks Chart

ABT Buybacks
$893.00M-31.43% 20Y
Zoom

Current Buybacks

$893.00M

$893.00 Million

Year-over-Year Change

-31.04%

vs. $1.29B prior year

Historical Data

28

Years of data available

Annual Buybacks History

YearBuybacksYoY Change% Change
2025$893.00M$-402.00M-31.04%
2024$1.29B+$68.00M+5.54%
2023$1.23B$-2.57B-67.67%
2022$3.79B+$1.50B+65.07%
2021$2.30B+$1.90B+470.47%
2020$403.00M$-315.00M-43.87%
2019$718.00M+$480.00M+201.68%
2018$238.00M$-589.00M-71.22%
2017$827.00M+$305.00M+58.43%
2016$522.00M$-1.72B-76.67%
2015$2.24B+$42.00M+1.91%
2014$2.19B+$590.00M+36.76%
2013$1.60B$-759.00M-32.11%
2012$2.36B+$2.29B+2969.85%
2011$77.01M$-789.82M-91.12%
2010$866.83M+$40.48M+4.90%
2009$826.35M$-255.46M-23.61%
2008$1.08B+$23.01M+2.17%
2007$1.06B+$304.29M+40.33%
2006$754.50M$-547.81M-42.06%
2005$1.30B+$802.57M+160.60%
2004$499.75M+$402.13M+411.94%
2003$97.62M+$80.25M+462.18%
2001$17.36M$-447.49M-96.26%
2000$464.86M$-411.44M-46.95%
1998$876.30M$-178.20M-16.90%
1997$1.05B+$245.70M+30.38%
1996$808.80M
Data as of Wednesday, June 10, 2026

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Abbott Park, IL
114,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Ford